KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Common Equity (2016 - 2025)

Historic Common Equity for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $31.3 billion.

  • Regeneron Pharmaceuticals' Common Equity rose 648.4% to $31.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $31.3 billion, marking a year-over-year increase of 648.4%. This contributed to the annual value of $31.3 billion for FY2025, which is 648.4% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Common Equity is $31.3 billion, which was up 648.4% from $31.0 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Common Equity registered a high of $31.3 billion during Q4 2025, and its lowest value of $12.0 billion during Q1 2021.
  • In the last 5 years, Regeneron Pharmaceuticals' Common Equity had a median value of $24.5 billion in 2023 and averaged $24.1 billion.
  • Over the last 5 years, Regeneron Pharmaceuticals' Common Equity had its largest YoY gain of 7044.1% in 2021, and its largest YoY loss of 128.57% in 2021.
  • Over the past 5 years, Regeneron Pharmaceuticals' Common Equity (Quarter) stood at $18.8 billion in 2021, then rose by 20.75% to $22.7 billion in 2022, then rose by 14.6% to $26.0 billion in 2023, then increased by 13.02% to $29.4 billion in 2024, then rose by 6.48% to $31.3 billion in 2025.
  • Its Common Equity stands at $31.3 billion for Q4 2025, versus $31.0 billion for Q3 2025 and $29.9 billion for Q2 2025.